Abstract 11907: The Association of Life’s Simple 7 Health Metrics and Incident Non-Cardiovascular Disease: The Multi-Ethnic Study of Atherosclerosis
Introduction: The American Heart Association (AHA) introduced the Life’s Simple 7 (LS7) health metrics to assess and promote cardiovascular health and wellness. Favorable LS7 status is associated with reduced risk of cardiovascular and all-cause mortality. We assessed the association between the LS7 health metrics and non-cardiovascular disease (non-CVD).
Methods: 6,814 participants (mean age 62 ±10 years, females 53%) from the Multi-Ethnic Study of Atherosclerosis (MESA) were followed for a median of 10.2 years. Each component of the LS7 metrics (smoking, body mass index, physical activity, diet, total cholesterol, blood pressure and blood glucose) was categorized into 3 according to AHA criteria and assigned points, ideal (2), intermediate (1) and poor (0). The LS7 health index, created from the metrics, was categorized into 3 levels based on total number of points achieved, ideal (11-14), intermediate (9-10) and poor (0-8). Cox proportional hazard ratios and incidence rate per 1000 person-years were calculated for hospital ICD-9 diagnoses of cancer, chronic kidney disease (CKD), pneumonia, chronic obstructive pulmonary disease (COPD), dementia and hip fracture. Analyses were adjusted for age, race/ethnicity, and socioeconomic status.
Results: Overall all non-CVD event rates were lower with improving LS7 health status (Figure 1). In multivariable adjusted models (Table 1), with the poor category of the LS7 health index as reference, individuals in the ideal category had a lower hazard for non-CVD events, 21% lower for cancer (95% CI 0.64-0.98), 62% lower for CKD (95% CI 0.27-0.53), 45% lower for pneumonia (95% CI 0.39-0.78) and 48% lower for COPD (95% CI 0.31-0.85).
Conclusion: The LS7 health index may identify vulnerability for multiple chronic conditions beyond CVD. These results suggest the implications of achieving the AHA’s national goal of ideal LS7 health metrics are favorable, as it will reduce the burden of many diseases as well as health care costs.
Author Disclosures: O. Ogunmoroti: None. N.B. Allen: None. E.D. Michos: None. T. Rundek: None. J. Rana: None. R. Blankstein: None. R.S. Blumenthal: None. M. Cushman: Research Grant; Significant; Diadexus. Honoraria; Significant; Diadexus. M.J. Blaha: None. E. Veledar: None. K. Nasir: Consultant/Advisory Board; Modest; Regeneron, Quest Diagnostic. Consultant/Advisory Board; Significant; Modest, Modest.
- © 2015 by American Heart Association, Inc.